Jiang X, et al. - Researchers focused on the clinical importance and functional role of long noncoding RNA (lncRNA) GIHCG in colorectal cancer (CRC). They used seven CRC cell lines and 110 CRC tissues to detect GIHCG expression and compared clinicopathological characteristics in the high GIHCG expression group and the low GIHCG expression group. They investigated the risk factors for poor overall survival (OS) and progression-free survival (PFS) via univariate and multivariate analyses. They also silenced GIHCG expression with siRNAs in LoVo cells and overexpressed with pcDNA3.1-GIHCG vector in SW480 cells, respectively. They also determine the role of GIHCG in the migration, invasion and proliferation of CRC cells. They found overexpression of GIHCG in seven CRC cell lines and 110 CRC tissues. Findings revealed a correlation of high GIHCG expression with lymphovascular invasion, lymph node metastasis, distant metastasis and advanced TNM stages. Much poorer OS and PFS rates were observed in patients with high GIHCG expression. Also, they found high GIHCG expression independently conferred risk for poor OS and PFS. Overall, the contribution of GIHCG to cancer progression and chemoresistance was shown. GIHCG indicated poor prognosis and could be a promising prognostic biomarker and therapeutic target in CRC.